文献速递慢病管理预防保健、筛查与疫苗

镰状细胞病中2型糖尿病的筛查与诊断

Screening and Diagnosis of Type 2 Diabetes in Sickle Cell Disease.
PubMed 文献 · J Am Board Fam Med · 2024-01-01

本文综述了镰状细胞病(SCD)患者中2型糖尿病(T2DM)的筛查与诊断证据,基于5篇符合纳入标准的文献,建议从35岁起使用空腹血糖作为标准筛查方法,不推荐使用HbA1c、果糖胺或糖化白蛋白进行筛查或诊断。

要点

  • SCD患者中HbA1c因血红蛋白变异而不可靠,不推荐用于T2DM筛查或诊断。
  • 推荐从35岁起以空腹血糖作为SCD患者T2DM的标准筛查方法。
  • 果糖胺和糖化白蛋白在SCD中的使用价值有限,不推荐用于筛查或诊断。

核心结论

  • 空腹血糖是SCD患者筛查T2DM的标准方法,有助于早期诊断并预防大血管和微血管并发症。

研究设计与样本

  • 本文为综合文献综述,检索PubMed、Standards of Medical Care in Diabetes、US Preventative Services Task Force、National Institute of Diabetes and Digestive and Kidney Diseases,最终纳入5篇符合标准的研究。

主要发现

  • 由于SCD患者存在血红蛋白变异,HbA1c诊断T2DM复杂且不准确。
  • 综述纳入的5篇文章支持在SCD患者中使用空腹血糖进行T2DM筛查和诊断。

关键数值与推荐

  • 根据USPSTF指南,推荐从35岁开始使用空腹血糖筛查T2DM。
  • 不推荐使用HbA1c、果糖胺或糖化白蛋白筛查或诊断SCD患者的T2DM。

临床怎么用

  • 全科医生应对SCD患者从35岁起采用空腹血糖筛查T2DM,避免使用HbA1c等指标。

局限性

  • 关于SCD患者T2DM诊断的研究有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diagnosing type 2 diabetes mellitus (T2DM) in people with sickle cell disease (SCD) is complicated due to hemoglobin A variance in affected individuals. Accurate screening assessments are needed to prevent excessive morbidity and mortality. Primary care physicians need recommendations for screening and diagnosis in this unique population. PURPOSE: To synthesize recommendations regarding medical diagnosis criteria for T2DM in SCD. DATA SOURCES: PubMed, Standards of Medical Care in Diabetes, US Preventative Services Task Force, National Institute of Diabetes and Digestive and Kidney Diseases, searched on December 28, 2022. STUDY SELECTION: One reviewer searched each database to select applicable studies pertaining to "sickle cell disease," "type 2 diabetes," "HbA1c," and "fructosamine" from December 28, 2022, to March 15, 2023. DATA EXTRACTION AND QUALITY ASSESSMENT: A comprehensive literature review was done to extract current data/facts and assess certainty of evidence. DATA SYNTHESIS: This review reviews 5 articles that met inclusion criteria to outline outpatient screening and diagnosis of T2DM in SCD. Based on these findings, we recommend fasting plasma glucose as the standard screening starting at age 35 based on USPSTF guidelines. We do not recommend using HbA1c, fructosamine, or glycated albumin for screening or diagnosis of T2DM in individuals with SCD; the latter entities have limited implications in their use. LIMITATIONS: There are limited studies available for diagnosis of T2DM in SCD. CONCLUSIONS: Fasting plasma glucose is the standard screening for T2DM for SCD to ensure early diagnosis and prevent worsening macro and microvascular complications from both comorbid conditions.

来源:J Am Board Fam Med,查看原文。版权归原作者所有。

引用

  1. Carrithers B, Klein R, Ovalle F, et al. Screening and Diagnosis of Type 2 Diabetes in Sickle Cell Disease. J Am Board Fam Med. 2024. PMID: 39978849. doi:10.3122/jabfm.2024.240042R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。